TLL-018, a Janus kinase 1/tyrosine kinase 2 inhibitor, proved more effective for treating patients with RA than tofacitinib, according to a study by Zeng et al.
Search results for: back pain
Heart Health: The Immunobiology of Cardiovascular Inflammation
How do inflammatory pathways strain the cardiovascular system? Dr. Mark Gorelik provided insights into the inflammatory processes that influence heart recovery after myocardial infarction, Kawasaki disease, multi-system inflammatory syndrome in children and more.
Is ‘Resilience’ a Positive Descriptive or an Insidious Bias?
Resilience. That word has been living rent free in my head for the past three weeks. And rent free is a bit of understatement. It all began at the end of a very productive clinic, when the trainee and I sat down to discuss our reflections on the interactions with patients that we’d had in…
Break the Barrier: Understanding & Treating Neuropsychiatric Lupus
Updated research on the complexities of central nervous system (CNS) lupus, as well as its diagnosis and treatment are discussed.
A Live Patient Experience in Medical School Can Boost Interest in, and Knowledge of, Rheumatology
After intense academic classroom studies, University of Nebraska College of Medicine students in Omaha are able to put what they are learning in practice through the university’s Live Patient Experience (LPE) program, led by the Division of Rheumatology and Immunology. The LPE gives students real-life experience with patients and can serve as motivation to consider…
Rheumatology Priorities Advanced at Busy AMA House of Delegates Meeting
Two ACR-led resolutions on in-office specialty drug dispensing and the proposed NIH Public Access Plan passed the House of Delegates and will become AMA policy.
Mixed Results for Rezpegaldesleukin in Patients with Active SLE
In a clinical trial, patients with active systemic lupus erythematosus (SLE) did not experience a reduction in disease activity with the addition of rezpegaldesleukin to their standard treatments. However, some patient populations did see improvements in their disease activity compared with the placebo-treated group.
FDA Issues Updated Prescribing Information for Opioids & Over-the-Counter Naloxone
New prescribing guidance has been issued by the FDA for immediate-release and extended-release/long-acting opioids for pain management. The agency also announced multiple label updates, which include changes to the Boxed Warnings.
RA Disease Activity & Alcohol Consumption Habits
Past studies have suggested that patients with rheumatoid arthritis (RA) who consume a moderate amount of alcohol may experience lower disease activity and higher quality of life than non-drinkers. In this study, Alfredsson, et al. confirmed earlier studies’ claims that alcohol consumption reduces disease activity in a dose-dependent manner, and also indicated that patients who stopped drinking post-baseline experienced worsened disease activity, more pain and a lower quality of life.
Slow but Steady: 2023 State Legislative Progress
This legislative season has seen key pharmacy benefit manager reforms but slow movement on other issues, such as copay accumulators and utilization management. The ACR is also monitoring emerging topics, such as biomarker testing and post-public health emergency telehealth reforms.
- « Previous Page
- 1
- …
- 48
- 49
- 50
- 51
- 52
- …
- 162
- Next Page »